SCHEMBL9608339

SCHEMBL9608339

CC(C)Cn1c(=O)n(C)c(=O)c2c(N(C)c3ccccc3)n(Cc3ccc(-n4cccc4)cc3)cc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 8/20 0.48
PDE1B Q01064 8/20 0.48
PDE1C Q14123 8/20 0.48
PDE2A O00408 5/20 0.48
SLC16A1 P53985 2/20 0.39
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 2/20 0.36
BRD4 O60885 1/20 0.35
LMNA P02545 1/20 0.34
CASP1 P29466 1/20 0.34
HTT P42858 1/20 0.34
CASP7 P55210 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2461101 0.90 PDE1A (0.50) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL2455867 0.83 PDE1A (0.49) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL9608337 0.81 PDE1B (0.48) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL13334753 0.81 PDE1A (0.43) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL2454975 0.72 PDE1B (0.51) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL2454858 0.70 PDE1A (0.48) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL9608334 0.69 PDE1B (0.52) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL2462419 0.69 PDE1A (0.46) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL9608351 0.67 PDE1A (0.44) PDE1APDE1BPDE1CPDE2ASLC16A1
SCHEMBL2461370 0.67 PDE1A (0.49) PDE1APDE1BPDE1CPDE2ASLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353556-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-12-10 US disclosed
US-8927556-B2 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds INTRA-CELLULAR THERAPIES, INC. (US) 2015-01-06 US disclosed
US-20120136013-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES. INC. 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353556-A1 ORGANIC COMPOUNDS CYP2C9, TPMT, CYP2C19 PDE1A 4874/4885PDE1B 4863/4885PDE1C 4862/4885
US-20120136013-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PDE1A 4874/4885PDE1B 4855/4885PDE1C 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.